 |
Home |
|---|---|
 |
|
|
|
IIPM |
|
|
|
|
|
Our Faculty |
|
|
|
|
Publications |
|
|
|
|
|
Fellowship Training |
|
|
|
|
|
Seminars & Events |
|
|
|
|
|
COBRA |
|
|
|
|
|
Drug Interactions |
|
|
|
|
|
Clinical Drug Use |
|
|
|
|
|
Medications in Pregnancy |
|
|
|
|
|
Analytical Core |
|
|
|
|
|
Contact Us |
|
|
|
Publications
- Jiang F, Desta Z, Shon JH, Yeo CW, Kim HS, Liu KH, Bae SK, Lee SS, Flockhart DA, Shin JG.
Effects of clopidogrel and itraconazole on the disposition of efavirenz and its hydroxyl-metabolites: exploration of a novel CYP2B6 phenotyping index.
Br J Clin Pharmacol. 2012 May 3;. - Kim KM, Murray MD, Tu W, Robarge J, Ding Y, Brater DC, Flockhart DA.
Pharmacogenetics and healthcare outcomes in patients with chronic heart failure.
Eur J Clin Pharmacol. 2012 Apr 29;. - Newman WG, Flockhart D.
Breast cancer pharmacogenomics: where we are going.
Pharmacogenomics. 2012 Apr;13(6):629-31. - Hennessy S, Flockhart DA.
The need for translational research on drug-drug interactions.
Clin Pharmacol Ther. 2012 May;91(5):771-3. - Philips S, Rae JM, Oesterreich S, Hayes DF, Stearns V, Henry NL, Storniolo AM, Flockhart DA, Skaar TC.
Whole genome amplification of DNA for genotyping pharmacogenetics candidate genes.
Front Pharmacol. 2012;3:54. - Kreutz RP, Breall JA, Kreutz Y, Owens J, Lu D, Bolad I, von der Lohe E, Sinha A, Flockhart DA.
Protease activated receptor-1 (PAR-1) mediated platelet aggregation is dependant on clopidogrel response.
Thromb Res. 2012 Mar 27;. - Zhang W, Ayan-Oshodi M, Willis BA, Annes W, Hall SD, Chiesa J, Seger M.
QT effect of semagacestat at therapeutic and supratherapeutic doses.
Int J Clin Pharmacol Ther. 2012 Apr;50(4):290-9. - Kreutz RP, Nystrom P, Kreutz Y, Miao J, Desta Z, Breall JA, Li L, Chiang C, Kovacs R, Flockhart DA, Jin Y.
Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response.
Clin Pharmacol. 2012;4:13-20. - Kreutz RP, Nystrom P, Kreutz Y, Miao J, Kovacs R, Desta Z, Flockhart DA, Jin Y.
Inhibition of platelet aggregation by prostaglandin E1 (PGE1) in diabetic patients during therapy with clopidogrel and aspirin.
Platelets. 2012 Mar 2;. - Henry NL, Azzouz F, Desta Z, Li L, Nguyen AT, Lemler S, Hayden J, Tarpinian K, Yakim E, Flockhart DA, Stearns V, Hayes DF, Storniolo AM.
Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer.
J Clin Oncol. 2012 Mar 20;30(9):936-42. - Michaud V, Ogburn E, Thong N, Aregbe AO, Quigg TC, Flockhart DA, Desta Z.
Induction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteers.
Clin Pharmacol Ther. 2012 Mar;91(3):475-82. - Ramamoorthy A, Li L, Gaedigk A, Bradford LD, Benson EA, Flockhart DA, Skaar TC.
In silico and in vitro identification of microRNAs that regulate hepatic nuclear factor 4α expression.
Drug Metab Dispos. 2012 Apr;40(4):726-33. - Mao J, Mohutsky MA, Harrelson JP, Wrighton SA, Hall SD.
Predictions of cytochrome P450-mediated drug-drug interactions using cryopreserved human hepatocytes: comparison of plasma and protein-free media incubation conditions.
Drug Metab Dispos. 2012 Apr;40(4):706-16. - Crews KR, Gaedigk A, Dunnenberger HM, Klein TE, Shen DD, Callaghan JT, Kharasch ED, Skaar TC.
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype.
Clin Pharmacol Ther. 2012 Feb;91(2):321-6. - Kiyotani K, Mushiroda T, Tsunoda T, Morizono T, Hosono N, Kubo M, Tanigawara Y, Imamura CK, Flockhart DA, Aki F, Hirata K, Takatsuka Y, Okazaki M, Ohsumi S, Yamakawa T, Sasa M, Nakamura Y, Zembutsu H.
A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese.
Hum Mol Genet. 2012 Apr 1;21(7):1665-72. - Bell LN, Nguyen AT, Li L, Desta Z, Henry NL, Hayes DF, Wolff AC, Stearns V, Storniolo AM, Flockhart DA.
Comparison of Changes in the Lipid Profile of Postmenopausal Women With Early Stage Breast Cancer Treated With Exemestane or Letrozole.
J Clin Pharmacol. 2011 Dec 15;. - Hartmaier RJ, Richter AS, Gillihan RM, Sallit JZ, McGuire SE, Wang J, Lee AV, Osborne CK, O'Malley BW, Brown PH, Xu J, Skaar TC, Philips S, Rae JM, Azzouz F, Li L, Hayden J, Henry NL, Nguyen AT, Stearns V, Hayes DF, Flockhart DA, Oesterreich S.
A SNP in steroid receptor coactivator-1 disrupts a GSK3β phosphorylation site and is associated with altered tamoxifen response in bone.
Mol Endocrinol. 2012 Feb;26(2):220-7. - Tisdale JE, Overholser BR, Wroblewski HA, Sowinski KM, Amankwa K, Borzak S, Kingery JR, Coram R, Zipes DP, Flockhart D, Kovacs RJ.
Enhanced Sensitivity to Drug-Induced QT Interval Lengthening in Patients With Heart Failure Due to Left Ventricular Systolic Dysfunction.
J Clin Pharmacol. 2011 Nov 1;. - Bardia A, Arieas ET, Zhang Z, Defilippis A, Tarpinian K, Jeter S, Nguyen A, Henry NL, Flockhart DA, Hayes DF, Hayden J, Storniolo AM, Armstrong DK, Davidson NE, Fetting J, Ouyang P, Wolff AC, Blumenthal RS, Ashen MD, Stearns V.
Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer.
Breast Cancer Res Treat. 2012 Feb;131(3):907-14. - Lu WJ, Zhou W, Kreutz Y, Flockhart DA.
Methadone adverse reaction presenting with large increase in plasma methadone binding: a case series.
J Med Case Rep. 2011 Oct 10;5:513. - Philips S, Richter A, Oesterreich S, Rae JM, Flockhart DA, Perumal NB, Skaar TC.
Functional characterization of a genetic polymorphism in the promoter of the ESR2 gene.
Horm Cancer. 2012 Apr;3(1-2):37-43. - Desta Z, Kreutz Y, Nguyen AT, Li L, Skaar T, Kamdem LK, Henry NL, Hayes DF, Storniolo AM, Stearns V, Hoffmann E, Tyndale RF, Flockhart DA.
Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age.
Clin Pharmacol Ther. 2011 Nov;90(5):693-700. - Lu WJ, Ferlito V, Xu C, Flockhart DA, Caccamese S.
Enantiomers of naringenin as pleiotropic, stereoselective inhibitors of cytochrome P450 isoforms.
Chirality. 2011 Sep 22;. - Thacker DL, Modak A, Nguyen PD, Flockhart DA, Desta Z.
Stereoselective pharmacokinetics of stable isotope (+/-)-[(13) C]-pantoprazole: Implications for a rapid screening phenotype test of CYP2C19 activity.
Chirality. 2011 Sep 20;. - Montenegro MF, Ceron CS, Salgado MC, Desta Z, Flockhart DA, Tanus-Santos JE.
Tamoxifen and its metabolites cause acute vasorelaxation of aortic rings by inducing vasodilator prostanoid synthesis.
J Cardiovasc Pharmacol. 2011 Dec;58(6):647-53. - Prowell TM, Blackford AL, Byrne C, Khouri NF, Dowsett M, Folkerd E, Tarpinian KS, Powers PP, Wright LA, Donehower MG, Jeter SC, Armstrong DK, Emens LA, Fetting JH, Wolff AC, Garrett-Mayer E, Skaar TC, Davidson NE, Stearns V.
Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole.
Cancer Prev Res (Phila). 2011 Dec;4(12):1993-2001. - Goetz MP, Schaid DJ, Wickerham DL, Safgren S, Mushiroda T, Kubo M, Batzler A, Costantino JP, Vogel VG, Paik S, Carlson EE, Flockhart DA, Wolmark N, Nakamura Y, Weinshilboum RM, Ingle JN, Ames MM.
Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials.
Clin Cancer Res. 2011 Nov 1;17(21):6944-51. - Wessels AM, Flockhart DA, Carpenter JS, Radovich M, Li L, Miller KD, Sledge GW, Storniolo AM, Otte JL, Lemler SM, Schneider BP.
Cytochrome P450 polymorphisms and their relationship with premature ovarian failure in premenopausal women with breast cancer receiving doxorubicin and cyclophosphamide.
Breast J. 2011 Sep-Oct;17(5):536-8. - Lu WJ, Xu C, Pei Z, Mayhoub AS, Cushman M, Flockhart DA.
The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents.
Breast Cancer Res Treat. 2012 May;133(1):99-109. - Euhus D, Bu D, Xie XJ, Sarode V, Ashfaq R, Hunt K, Xia W, O'Shaughnessy J, Grant M, Arun B, Dooley W, Miller A, Flockhart D, Lewis C.
Tamoxifen downregulates ets oncogene family members ETV4 and ETV5 in benign breast tissue: implications for durable risk reduction.
Cancer Prev Res (Phila). 2011 Nov;4(11):1852-62. - Irvin WJ Jr, Walko CM, Weck KE, Ibrahim JG, Chiu WK, Dees EC, Moore SG, Olajide OA, Graham ML, Canale ST, Raab RE, Corso SW, Peppercorn JM, Anderson SM, Friedman KJ, Ogburn ET, Desta Z, Flockhart DA, McLeod HL, Evans JP, Carey LA.
Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study.
J Clin Oncol. 2011 Aug 20;29(24):3232-9. - Haas DM, Gallauresi B, Shields K, Zeitlin D, Clark SM, Hebert MF, Ren Z, Nallani SC, Meslin EM, Feibus KB, Koren G, Goebel WS, Easterling T, Denne SC, Flockhart DA, Renbarger JL.
Pharmacotherapy and pregnancy: highlights from the Third International Conference for Individualized Pharmacotherapy in Pregnancy.
Clin Transl Sci. 2011 Jun;4(3):204-9. - Kreutz RP, Alloosh M, Mansour K, Neeb Z, Kreutz Y, Flockhart DA, Sturek M.
Morbid obesity and metabolic syndrome in Ossabaw miniature swine are associated with increased platelet reactivity.
Diabetes Metab Syndr Obes. 2011;4:99-105. - Yoon HH, Catalano PJ, Murphy KM, Skaar TC, Philips S, Powell M, Montgomery EA, Hafez MJ, Offer SM, Liu G, Meltzer SJ, Wu X, Forastiere AA, Benson AB, Kleinberg LR, Gibson MK.
Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group.
BMC Cancer. 2011 May 17;11:176. - Shen C, Huang Y, Liu Y, Wang G, Zhao Y, Wang Z, Teng M, Wang Y, Flockhart DA, Skaar TC, Yan P, Nephew KP, Huang TH, Li L.
A modulated empirical Bayes model for identifying topological and temporal estrogen receptor α regulatory networks in breast cancer.
BMC Syst Biol. 2011 May 9;5:67. - Ramamoorthy A, Skaar TC.
In silico identification of microRNAs predicted to regulate the drug metabolizing cytochrome P450 genes.
Drug Metab Lett. 2011 Apr;5(2):126-31. - Ramamoorthy A, Skaar TC.
Gene copy number variations: it is important to determine which allele is affected.
Pharmacogenomics. 2011 Mar;12(3):299-301. - Lu WJ, Desta Z, Flockhart DA.
Tamoxifen metabolites as active inhibitors of aromatase in the treatment of breast cancer.
Breast Cancer Res Treat. 2012 Jan;131(2):473-81. - Lehmann AS, Haas DM, McCormick CL, Skaar TC, Renbarger JL.
Collection of human genomic DNA from neonates: a comparison between umbilical cord blood and buccal swabs.
Am J Obstet Gynecol. 2011 Apr;204(4):362.e1-6. - Yoon HH, Catalano P, Gibson MK, Skaar TC, Philips S, Montgomery EA, Hafez MJ, Powell M, Liu G, Forastiere AA, Benson AB, Kleinberg LR, Murphy KM.
Genetic variation in radiation and platinum pathways predicts severe acute radiation toxicity in patients with esophageal adenocarcinoma treated with cisplatin-based preoperative radiochemotherapy: results from the Eastern Cooperative Oncology Group.
Cancer Chemother Pharmacol. 2011 Oct;68(4):863-70. - Mao J, Mohutsky MA, Harrelson JP, Wrighton SA, Hall SD.
Prediction of CYP3A-mediated drug-drug interactions using human hepatocytes suspended in human plasma.
Drug Metab Dispos. 2011 Apr;39(4):591-602. - Kamdem LK, Liu Y, Stearns V, Kadlubar SA, Ramirez J, Jeter S, Shahverdi K, Ward BA, Ogburn E, Ratain MJ, Flockhart DA, Desta Z.
In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole.
Br J Clin Pharmacol. 2010 Dec;70(6):854-69. - Freedman AN, Sansbury LB, Figg WD, Potosky AL, Weiss Smith SR, Khoury MJ, Nelson SA, Weinshilboum RM, Ratain MJ, McLeod HL, Epstein RS, Ginsburg GS, Schilsky RL, Liu G, Flockhart DA, Ulrich CM, Davis RL, Lesko LJ, Zineh I, Randhawa G, Ambrosone CB, Relling MV, Rothman N, Xie H, Spitz MR, Ballard-Barbash R, Doroshow JH, Minasian LM.
Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.
J Natl Cancer Inst. 2010 Nov 17;102(22):1698-705. - Kamdem LK, Flockhart DA, Desta Z.
In vitro cytochrome P450-mediated metabolism of exemestane.
Drug Metab Dispos. 2011 Jan;39(1):98-105. - Ingle JN, Schaid DJ, Goss PE, Liu M, Mushiroda T, Chapman JA, Kubo M, Jenkins GD, Batzler A, Shepherd L, Pater J, Wang L, Ellis MJ, Stearns V, Rohrer DC, Goetz MP, Pritchard KI, Flockhart DA, Nakamura Y, Weinshilboum RM.
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.
J Clin Oncol. 2010 Nov 1;28(31):4674-82. - Hayes DF, Skaar TC, Rae JM, Henry NL, Nguyen AT, Stearns V, Li L, Philips S, Desta Z, Flockhart DA.
Estrogen receptor genotypes, menopausal status, and the effects of tamoxifen on lipid levels: revised and updated results.
Clin Pharmacol Ther. 2010 Nov;88(5):626-9. - Kreutz RP, Stanek EJ, Aubert R, Yao J, Breall JA, Desta Z, Skaar TC, Teagarden JR, Frueh FW, Epstein RS, Flockhart DA.
Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study.
Pharmacotherapy. 2010 Aug;30(8):787-96. - Henry NL, Pchejetski D, A'Hern R, Nguyen AT, Charles P, Waxman J, Li L, Storniolo AM, Hayes DF, Flockhart DA, Stearns V, Stebbing J.
Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study.
Br J Cancer. 2010 Jul 27;103(3):291-6. - Radovich M, Hancock BA, Kassem N, Mi D, Skaar TC, Schneider BP.
Resequencing of the vascular endothelial growth factor promoter reveals haplotype structure and functional diversity.
Angiogenesis. 2010 Sep;13(3):211-8. - Li L, Borges S, Jason RD, Shen C, Desta Z, Flockhart D.
A penalized mixture model approach in genotype/phenotype association analysis for quantitative phenotypes.
Cancer Inform. 2010 Apr 27;9:93-103. - Rand KL, Otte JL, Flockhart D, Hayes D, Storniolo AM, Stearns V, Henry NL, Nguyen A, Lemler S, Hayden J, Jeter S, Carpenter JS.
Modeling hot flushes and quality of life in breast cancer survivors.
Climacteric. 2011 Feb;14(1):171-80. - Haas DM, Hebert MF, Soldin OP, Flockhart DA, Madadi P, Nocon JJ, Chambers CD, Hankins GD, Clark S, Wisner KL, Li L, Renbarger JL, Learman LA.
Pharmacotherapy and pregnancy: highlights from the Second International Conference for Individualized Pharmacotherapy in Pregnancy.
Clin Transl Sci. 2009 Dec;2(6):439-43. - Ramamoorthy A, Flockhart DA, Hosono N, Kubo M, Nakamura Y, Skaar TC.
Differential quantification of CYP2D6 gene copy number by four different quantitative real-time PCR assays.
Pharmacogenet Genomics. 2010 Jul;20(7):451-4. - Lu WJ, Bies R, Kamden LK, Desta Z, Flockhart DA.
Methadone: a substrate and mechanism-based inhibitor of CYP19 (aromatase).
Drug Metab Dispos. 2010 Aug;38(8):1308-13. - Ingle JN, Buzdar AU, Schaid DJ, Goetz MP, Batzler A, Robson ME, Northfelt DW, Olson JE, Perez EA, Desta Z, Weintraub RA, Williard CV, Flockhart DA, Weinshilboum RM.
Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer.
Cancer Res. 2010 Apr 15;70(8):3278-86. - Kiyotani K, Mushiroda T, Imamura CK, Hosono N, Tsunoda T, Kubo M, Tanigawara Y, Flockhart DA, Desta Z, Skaar TC, Aki F, Hirata K, Takatsuka Y, Okazaki M, Ohsumi S, Yamakawa T, Sasa M, Nakamura Y, Zembutsu H.
Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients.
J Clin Oncol. 2010 Mar 10;28(8):1287-93. - Borges S, Desta Z, Jin Y, Faouzi A, Robarge JD, Philips S, Nguyen A, Stearns V, Hayes D, Rae JM, Skaar TC, Flockhart DA, Li L.
Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients.
J Clin Pharmacol. 2010 Apr;50(4):450-8. - Hartmaier RJ, Tchatchou S, Richter AS, Wang J, McGuire SE, Skaar TC, Rae JM, Hemminki K, Sutter C, Ditsch N, Bugert P, Weber BH, Niederacher D, Arnold N, Varon-Mateeva R, Wappenschmidt B, Schmutzler RK, Meindl A, Bartram CR, Burwinkel B, Oesterreich S.
Nuclear receptor coregulator SNP discovery and impact on breast cancer risk.
BMC Cancer. 2009 Dec 14;9:438. - Henry NL, Nguyen A, Azzouz F, Li L, Robarge J, Philips S, Cao D, Skaar TC, Rae JM, Storniolo AM, Flockhart DA, Hayes DF, Stearns V.
Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy.
Br J Cancer. 2010 Jan 19;102(2):294-300. - Zhang X, Galinsky RE, Kimura RE, Quinney SK, Jones DR, Hall SD.
Inhibition of CYP3A by erythromycin: in vitro-in vivo correlation in rats.
Drug Metab Dispos. 2010 Jan;38(1):61-72. - Arefayene M, Philips S, Cao D, Mamidipalli S, Desta Z, Flockhart DA, Wilkes DS, Skaar TC.
Identification of genetic variants in the human indoleamine 2,3-dioxygenase (IDO1) gene, which have altered enzyme activity.
Pharmacogenet Genomics. 2009 Jun;19(6):464-76. - Desta Z, Nguyen A, Flockhart D, Skaar T, Fletcher R, Weinshilboum R, Berlin DS, Klein TE, Altman RB.
Antiestrogen pathway (aromatase inhibitor).
Pharmacogenet Genomics. 2009 Jul;19(7):554-5. - Otte JL, Flockhart D, Hayes D, Storniolo AM, Stearns V, Schneider B, Henry NL, Azzouz F, Nguyen A, Lemler S, Hayden J, Jeter S, Wright L, Carpenter JS.
Comparison of subjective and objective hot flash measures over time among breast cancer survivors initiating aromatase inhibitor therapy.
Menopause. 2009 Jul-Aug;16(4):653-9. - Rae JM, Sikora MJ, Henry NL, Li L, Kim S, Oesterreich S, Skaar TC, Nguyen AT, Desta Z, Storniolo AM, Flockhart DA, Hayes DF, Stearns V.
Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients.
Pharmacogenomics J. 2009 Aug;9(4):258-64. - Montenegro MF, Pessa LR, Gomes VA, Desta Z, Flockhart DA, Tanus-Santos JE.
Assessment of vascular effects of tamoxifen and its metabolites on the rat perfused hindquarter vascular bed.
Basic Clin Pharmacol Toxicol. 2009 May;104(5):400-7. - Flockhart DA, Skaar T, Berlin DS, Klein TE, Nguyen AT.
Clinically available pharmacogenomics tests.
Clin Pharmacol Ther. 2009 Jul;86(1):109-13. - Carpenter JS, Yu M, Wu J, Von Ah D, Milata J, Otte JL, Johns S, Schneider B, Storniolo AM, Salomon R, Desta Z, Cao D, Jin Y, Philips S, Skaar TC.
Evaluating the role of serotonin in hot flashes after breast cancer using acute tryptophan depletion.
Menopause. 2009 Jul-Aug;16(4):644-52. - Higgins MJ, Rae JM, Flockhart DA, Hayes DF, Stearns V.
Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?
J Natl Compr Canc Netw. 2009 Feb;7(2):203-13. - Jeong S, Woo MM, Flockhart DA, Desta Z.
Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4'-methanol-bisbenzonitrile in vitro.
Cancer Chemother Pharmacol. 2009 Oct;64(5):867-75. - Haas DM, Renbarger JL, Denne S, Ahmed MS, Easterling T, Feibus K, Meslin EM, Koren G, Zajicek A, Snodgrass WR, Flockhart DA.
Pharmacotherapy and pregnancy: Highlights from the first International Conference for Individualized Pharmacotherapy in Pregnancy.
Clin Transl Sci. 2009 Feb;2(1):11-4. - Henry NL, Rae JM, Li L, Azzouz F, Skaar TC, Desta Z, Sikora MJ, Philips S, Nguyen AT, Storniolo AM, Hayes DF, Flockhart DA, Stearns V.
Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort.
Breast Cancer Res Treat. 2009 Oct;117(3):571-5. - Desta Z, Modak A, Nguyen PD, Lemler SM, Kurogi Y, Li L, Flockhart DA.
Rapid identification of the hepatic cytochrome P450 2C19 activity using a novel and noninvasive [13C]pantoprazole breath test.
J Pharmacol Exp Ther. 2009 Apr;329(1):297-305. - Onitilo AA, McCarty CA, Wilke RA, Glurich I, Engel JM, Flockhart DA, Nguyen A, Li L, Mi D, Skaar TC, Jin Y.
Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy.
Breast Cancer Res Treat. 2009 Jun;115(3):643-50. - Tisdale JE, Overholser BR, Sowinski KM, Wroblewski HA, Amankwa K, Borzak S, Kingery JR, Coram R, Zipes DP, Flockhart DA, Kovacs RJ.
Pharmacokinetics of ibutilide in patients with heart failure due to left ventricular systolic dysfunction.
Pharmacotherapy. 2008 Dec;28(12):1461-70. - Jin Y, Hayes DF, Li L, Robarge JD, Skaar TC, Philips S, Nguyen A, Schott A, Hayden J, Lemler S, Storniolo AM, Flockhart DA, Stearns V.
Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy.
J Clin Oncol. 2008 Dec 20;26(36):5849-54. - Li L, Yu M, Jason RD, Shen C, Azzouz F, McLeod HL, Borges-Gonzales S, Nguyen A, Skaar T, Desta Z, Sweeney CJ, Flockhart DA.
A mixture model approach in gene-gene and gene-environmental interactions for binary phenotypes.
J Biopharm Stat. 2008;18(6):1150-77. - Haas DM, Renbarger JL, Meslin EM, Drabiak K, Flockhart D.
Patient attitudes toward genotyping in an urban women's health clinic.
Obstet Gynecol. 2008 Nov;112(5):1023-8. - Limdi NA, Beasley TM, Crowley MR, Goldstein JA, Rieder MJ, Flockhart DA, Arnett DK, Acton RT, Liu N.
VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans.
Pharmacogenomics. 2008 Oct;9(10):1445-58. - Henry NL, Stearns V, Flockhart DA, Hayes DF, Riba M.
Drug interactions and pharmacogenomics in the treatment of breast cancer and depression.
Am J Psychiatry. 2008 Oct;165(10):1251-5. - Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S, Miller KD.
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.
J Clin Oncol. 2008 Oct 1;26(28):4672-8. - Goetz MP, Suman VJ, Couch FJ, Ames MM, Rae JM, Erlander MG, Ma XJ, Sgroi DC, Reynolds CA, Lingle WL, Weinshilboum RM, Flockhart DA, Desta Z, Perez EA, Ingle JN.
Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance.
Clin Cancer Res. 2008 Sep 15;14(18):5864-8. - Schneider BP, Radovich M, Flockhart DA, Carpenter JS, Li L, Robarge JD, Storniolo AM, Hancock BA, Skaar TC, Sledge GW.
Exploratory study evaluating the association of polymorphisms of angiogenesis genes with hot flashes.
Breast Cancer Res Treat. 2009 Aug;116(3):543-9. - Flockhart D.
CYP2D6 genotyping and the pharmacogenetics of tamoxifen.
Clin Adv Hematol Oncol. 2008 Jul;6(7):493-4. - Flockhart DA, Abernethy DR.
Finding the right research question: quality science depends on quality careers.
Clin Pharmacol Ther. 2008 Sep;84(3):427-9. - Weiss ST, McLeod HL, Flockhart DA, Dolan ME, Benowitz NL, Johnson JA, Ratain MJ, Giacomini KM.
Creating and evaluating genetic tests predictive of drug response.
Nat Rev Drug Discov. 2008 Jul;7(7):568-74. - Hayes DF, Stearns V, Rae J, Flockhart D.
A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients?
J Natl Cancer Inst. 2008 May 7;100(9):610-3. - Flockhart DA, O'Kane D, Williams MS, Watson MS, Flockhart DA, Gage B, Gandolfi R, King R, Lyon E, Nussbaum R, O'Kane D, Schulman K, Veenstra D, Williams MS, Watson MS.
Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin.
Genet Med. 2008 Feb;10(2):139-50. - Rae JM, Skaar TC, Hilsenbeck SG, Oesterreich S.
The role of single nucleotide polymorphisms in breast cancer metastasis.
Breast Cancer Res. 2008;10(1):301. - Carpenter JS, Flockhart D.
Flash points.
J Clin Oncol. 2007 Dec 10;25(35):5546-7. - Desta Z, Flockhart DA.
Germline pharmacogenetics of tamoxifen response: have we learned enough?
J Clin Oncol. 2007 Nov 20;25(33):5147-9. - Wilke RA, Lin DW, Roden DM, Watkins PB, Flockhart D, Zineh I, Giacomini KM, Krauss RM.
Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges.
Nat Rev Drug Discov. 2007 Nov;6(11):904-16. - Henry NL, Giles JT, Ang D, Mohan M, Dadabhoy D, Robarge J, Hayden J, Lemler S, Shahverdi K, Powers P, Li L, Flockhart D, Stearns V, Hayes DF, Storniolo AM, Clauw DJ.
Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors.
Breast Cancer Res Treat. 2008 Sep;111(2):365-72. - Schneider BP, Radovich M, Sledge GW, Robarge JD, Li L, Storniolo AM, Lemler S, Nguyen AT, Hancock BA, Stout M, Skaar T, Flockhart DA.
Association of polymorphisms of angiogenesis genes with breast cancer.
Breast Cancer Res Treat. 2008 Sep;111(1):157-63. - Li L, Hui S, Pennello G, Desta Z, Todd S, Nguyen A, Flockhart D.
Estimating a positive false discovery rate for variable selection in pharmacogenetic studies.
J Biopharm Stat. 2007;17(5):883-902. - Ntukidem NI, Nguyen AT, Stearns V, Rehman M, Schott A, Skaar T, Jin Y, Blanche P, Li L, Lemler S, Hayden J, Krauss RM, Desta Z, Flockhart DA, Hayes DF.
Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen.
Clin Pharmacol Ther. 2008 May;83(5):702-10. - Robarge JD, Li L, Desta Z, Nguyen A, Flockhart DA.
The star-allele nomenclature: retooling for translational genomics.
Clin Pharmacol Ther. 2007 Sep;82(3):244-8. - Desta Z, Saussele T, Ward B, Blievernicht J, Li L, Klein K, Flockhart DA, Zanger UM.
Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro.
Pharmacogenomics. 2007 Jun;8(6):547-58. - Bouker KB, Skaar TC, Harburger DS, Riggins RB, Fernandez DR, Zwart A, Clarke R.
The A4396G polymorphism in interferon regulatory factor 1 is frequently expressed in breast cancer cell lines.
Cancer Genet Cytogenet. 2007 May;175(1):61-4. - Altman RB, Benowitz N, Gurwitz D, Lunshof J, Relling M, Lamba J, Wieben E, Mooney S, Giacomini K, Weiss S, Johnson JA, McLeod H, Flockhart D, Weinshilboum R, Shuldiner AR, Roden D, Krauss RM, Ratain M.
Genetic nondiscrimination legislation: a critical prerequisite for pharmacogenomics data sharing.
Pharmacogenomics. 2007 May;8(5):519. - Li L, Yu M, Chin R, Lucksiri A, Flockhart DA, Hall SD.
Drug-drug interaction prediction: a Bayesian meta-analysis approach.
Stat Med. 2007 Sep 10;26(20):3700-21. - Giacomini KM, Brett CM, Altman RB, Benowitz NL, Dolan ME, Flockhart DA, Johnson JA, Hayes DF, Klein T, Krauss RM, Kroetz DL, McLeod HL, Nguyen AT, Ratain MJ, Relling MV, Reus V, Roden DM, Schaefer CA, Shuldiner AR, Skaar T, Tantisira K, Tyndale RF, Wang L, Weinshilboum RM, Weiss ST, Zineh I.
The pharmacogenetics research network: from SNP discovery to clinical drug response.
Clin Pharmacol Ther. 2007 Mar;81(3):328-45. - Nguyen A, Desta Z, Flockhart DA.
Enhancing race-based prescribing precision with pharmacogenomics.
Clin Pharmacol Ther. 2007 Mar;81(3):323-5. - Preskorn SH, Greenblatt DJ, Flockhart D, Luo Y, Perloff ES, Harmatz JS, Baker B, Klick-Davis A, Desta Z, Burt T.
Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers.
J Clin Psychopharmacol. 2007 Feb;27(1):28-34. - Roden DM, Altman RB, Benowitz NL, Flockhart DA, Giacomini KM, Johnson JA, Krauss RM, McLeod HL, Ratain MJ, Relling MV, Ring HZ, Shuldiner AR, Weinshilboum RM, Weiss ST.
Pharmacogenomics: challenges and opportunities.
Ann Intern Med. 2006 Nov 21;145(10):749-57. - Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Weinshilboum RM, Fritcher EG, Nibbe AM, Desta Z, Nguyen A, Flockhart DA, Perez EA, Ingle JN.
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.
Breast Cancer Res Treat. 2007 Jan;101(1):113-21. - Shin JG, Kang WK, Shon JH, Arefayene M, Yoon YR, Kim KA, Kim DI, Kim DS, Cho KH, Woosley RL, Flockhart DA.
Possible interethnic differences in quinidine-induced QT prolongation between healthy Caucasian and Korean subjects.
Br J Clin Pharmacol. 2007 Feb;63(2):206-15. - Sandrim VC, Yugar-Toledo JC, Desta Z, Flockhart DA, Moreno H Jr, Tanus-Santos JE.
Endothelial nitric oxide synthase haplotypes are related to blood pressure elevation, but not to resistance to antihypertensive drug therapy.
J Hypertens. 2006 Dec;24(12):2393-7. - Stearns V, Schneider B, Henry NL, Hayes DF, Flockhart DA.
Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants.
Nat Rev Cancer. 2006 Nov;6(11):886-93. - Preskorn SH, Borges-Gonzalez S, Flockhart D.
Clinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: Part II.
J Psychiatr Pract. 2006 Sep;12(5):312-6. - Knoderer HM, Robarge J, Flockhart DA.
Predicting asparaginase-associated pancreatitis.
Pediatr Blood Cancer. 2007 Oct 15;49(5):634-9. - Preskorn SH, Borges S, Flockhart D.
Clinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: part I.
J Psychiatr Pract. 2006 Jul;12(4):244-9. - Evans BJ, Flockhart DA.
The unfinished business of U.S. drug safety regulation.
Food Drug Law J. 2006;61(1):45-63. - Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, Jin Y, Storniolo AM, Nikoloff DM, Wu L, Hillman G, Hayes DF, Stearns V, Flockhart DA.
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.
Clin Pharmacol Ther. 2006 Jul;80(1):61-74. - Lim YC, Li L, Desta Z, Zhao Q, Rae JM, Flockhart DA, Skaar TC.
Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells.
J Pharmacol Exp Ther. 2006 Aug;318(2):503-12. - Chien JY, Lucksiri A, Ernest CS 2nd, Gorski JC, Wrighton SA, Hall SD.
Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole.
Drug Metab Dispos. 2006 Jul;34(7):1208-19. - Schneider BP, Skaar TC, Sledge GW, Badve S, Li L, Flockhart DA.
Analysis of angiogenesis genes from paraffin-embedded breast tumor and lymph nodes.
Breast Cancer Res Treat. 2006 Apr;96(3):209-15. - Bernard S, Neville KA, Nguyen AT, Flockhart DA.
Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications.
Oncologist. 2006 Feb;11(2):126-35. - Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, Desta Z, Perez EA, Ingle JN.
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.
J Clin Oncol. 2005 Dec 20;23(36):9312-8. - Andersson T, Flockhart DA, Goldstein DB, Huang SM, Kroetz DL, Milos PM, Ratain MJ, Thummel K.
Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests.
Clin Pharmacol Ther. 2005 Dec;78(6):559-81. - Rae JM, Goetz MP, Hayes DF, Ingle JN, Li L, Storniolo AM, Stearns V, Flockhart DA.
CYP2D6 genotype and tamoxifen response.
Breast Cancer Res. 2005 Jul 29;7(5):E6. - Metzger IF, Souza-Costa DC, Marroni AS, Nagassaki S, Desta Z, Flockhart DA, Tanus-Santos JE.
Endothelial nitric oxide synthase gene haplotypes associated with circulating concentrations of nitric oxide products in healthy men.
Pharmacogenet Genomics. 2005 Aug;15(8):565-70. - Bouker KB, Skaar TC, Riggins RB, Harburger DS, Fernandez DR, Zwart A, Wang A, Clarke R.
Interferon regulatory factor-1 (IRF-1) exhibits tumor suppressor activities in breast cancer associated with caspase activation and induction of apoptosis.
Carcinogenesis. 2005 Sep;26(9):1527-35. - Lippman ME, Benz C, Chinnaiyan A, Flockhart D, Harris A, Hudis C, Osborne CK, Press MF, Rae J, Sledge GW, Van't Veer L, Wicha M.
Consensus statement: Expedition Inspiration 2004 Breast Cancer Symposium 'Breast Cancer--The Development and Validation of New Therapeutics'.
Breast Cancer Res Treat. 2005 Mar;90(1):1-3. - Adigun AQ, Pinto AG, Flockhart DA, Gorski JC, Li L, Hall SD, Chalasani N.
Effect of cirrhosis and liver transplantation on the gender difference in QT interval.
Am J Cardiol. 2005 Mar 1;95(5):691-4. - Lim YC, Desta Z, Flockhart DA, Skaar TC.
Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen.
Cancer Chemother Pharmacol. 2005 May;55(5):471-8. - Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A, Blanchard R, Nguyen A, Ullmer L, Hayden J, Lemler S, Weinshilboum RM, Rae JM, Hayes DF, Flockhart DA.
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.
J Natl Cancer Inst. 2005 Jan 5;97(1):30-9. - Ho H, Pinto A, Hall SD, Flockhart DA, Li L, Skaar TC, Cadman P, O'Connor DT, Wagner U, Fineberg NS, Weinberger MH.
Association between the CYP3A5 genotype and blood pressure.
Hypertension. 2005 Feb;45(2):294-8. - Evans BJ, Flockhart DA, Meslin EM.
Creating incentives for genomic research to improve targeting of therapies.
Nat Med. 2004 Dec;10(12):1289-91. - Vitseva O, Flockhart DA, Jin Y, Varghese S, Freedman JE.
The effects of tamoxifen and its metabolites on platelet function and release of reactive oxygen intermediates.
J Pharmacol Exp Ther. 2005 Mar;312(3):1144-50. - Harvey AT, Flockhart D, Gorski JC, Greenblatt DJ, Burke M, Werder S, Preskorn SH.
Intramuscular haloperidol or lorazepam and QT intervals in schizophrenia.
J Clin Pharmacol. 2004 Oct;44(10):1173-84. - Ward BA, Morocho A, Kandil A, Galinsky RE, Flockhart DA, Desta Z.
Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro.
Br J Clin Pharmacol. 2004 Sep;58(3):277-87. - Ramírez J, Innocenti F, Schuetz EG, Flockhart DA, Relling MV, Santucci R, Ratain MJ.
CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes.
Drug Metab Dispos. 2004 Sep;32(9):930-6. - Li L, Desai M, Desta Z, Flockhart D.
QT analysis: a complex answer to a 'simple' problem.
Stat Med. 2004 Sep 15;23(17):2625-43. - Le Corre P, Parmer RJ, Kailasam MT, Kennedy BP, Skaar TP, Ho H, Leverge R, Smith DW, Ziegler MG, Insel PA, Schork NJ, Flockhart DA, O'connor DT.
Human sympathetic activation by alpha2-adrenergic blockade with yohimbine: Bimodal, epistatic influence of cytochrome P450-mediated drug metabolism.
Clin Pharmacol Ther. 2004 Aug;76(2):139-53. - Takada K, Arefayene M, Desta Z, Yarboro CH, Boumpas DT, Balow JE, Flockhart DA, Illei GG.
Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis.
Arthritis Rheum. 2004 Jul;50(7):2202-10. - Bouker KB, Skaar TC, Fernandez DR, O'Brien KA, Riggins RB, Cao D, Clarke R.
interferon regulatory factor-1 mediates the proapoptotic but not cell cycle arrest effects of the steroidal antiestrogen ICI 182,780 (faslodex, fulvestrant).
Cancer Res. 2004 Jun 1;64(11):4030-9. - Flores DL, Alvarado I, Wong ML, Licinio J, Flockhart D.
Clinical implications of genetic polymorphism of CYP2D6 in Mexican Americans.
Ann Intern Med. 2004 Jun 1;140(11):W71. - Rosenshein B, Flockhart DA, Ho H.
Induction of testosterone metabolism by esomeprazole in a CYP2C19*2 heterozygote.
Am J Med Sci. 2004 May;327(5):289-93. - Desta Z, Ward BA, Soukhova NV, Flockhart DA.
Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.
J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75. - Flockhart DA, Nelson HS.
Single isomer versus racemate: is there a difference? Clinical comparisons in allergy and gastroenterology.
CNS Spectr. 2002 Apr;7(4 Suppl 1):23-7. - Johnson MD, Zuo H, Lee KH, Trebley JP, Rae JM, Weatherman RV, Desta Z, Flockhart DA, Skaar TC.
Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen.
Breast Cancer Res Treat. 2004 May;85(2):151-9. - Stearns V, Davidson NE, Flockhart DA.
Pharmacogenetics in the treatment of breast cancer.
Pharmacogenomics J. 2004;4(3):143-53. - Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, Flockhart DA.
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
J Natl Cancer Inst. 2003 Dec 3;95(23):1758-64. - Zeng G, Hu Z, Kinch MS, Pan CX, Flockhart DA, Kao C, Gardner TA, Zhang S, Li L, Baldridge LA, Koch MO, Ulbright TM, Eble JN, Cheng L.
High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia.
Am J Pathol. 2003 Dec;163(6):2271-6. - Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, Zhu Y, Skaar TC, Gomez B, O'Brien K, Wang Y, Hilakivi-Clarke LA.
Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling.
Oncogene. 2003 Oct 20;22(47):7316-39. - Rae JM, Cordero KE, Scheys JO, Lippman ME, Flockhart DA, Johnson MD.
Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples.
Pharmacogenetics. 2003 Aug;13(8):501-7. - Desai M, Li L, Desta Z, Malik M, Flockhart D.
Variability of heart rate correction methods for the QT interval.
Br J Clin Pharmacol. 2003 Jun;55(6):511-7. - Lee KH, Ward BA, Desta Z, Flockhart DA, Jones DR.
Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial.
J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Jul 5;791(1-2):245-53. - Desai M, Tanus-Santos JE, Li L, Gorski JC, Arefayene M, Liu Y, Desta Z, Flockhart DA.
Pharmacokinetics and QT interval pharmacodynamics of oral haloperidol in poor and extensive metabolizers of CYP2D6.
Pharmacogenomics J. 2003;3(2):105-13. - Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z.
The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity.
J Pharmacol Exp Ther. 2003 Jul;306(1):287-300. - Arefayene M, Skaar TC, Zhao X, Rae JM, Tanus-Santos JE, Brinkmann U, Brehm I, Salat U, Nguyen A, Desta Z, Flockhart DA.
Sequence diversity and functional characterization of the 5'-regulatory region of human CYP2C19.
Pharmacogenetics. 2003 Apr;13(4):199-206. - Rosebraugh CJ, Tsong Y, Zhou F, Chen M, Mackey AC, Flowers C, Toyer D, Flockhart DA, Honig PK.
Improving the quality of adverse drug reaction reporting by 4th-year medical students.
Pharmacoepidemiol Drug Saf. 2003 Mar;12(2):97-101. - Flockhart DA, Rae JM.
Cytochrome P450 3A pharmacogenetics: the road that needs traveled.
Pharmacogenomics J. 2003;3(1):3-5. - Nikoloff D, Shim JC, Fairchild M, Patten N, Fijal BA, Koch WH, MacPherson A, Flockhart D, Yoon YR, Yoon JS, Kim YH, Shin JG.
Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics.
Pharmacogenomics J. 2002;2(6):400-7. - Altman RB, Flockhart DA, Sherry ST, Oliver DE, Rubin DL, Klein TE.
Indexing pharmacogenetic knowledge on the World Wide Web.
Pharmacogenetics. 2003 Jan;13(1):3-5. - Williams JA, Ring BJ, Cantrell VE, Campanale K, Jones DR, Hall SD, Wrighton SA.
Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes.
Drug Metab Dispos. 2002 Nov;30(11):1266-73. - Shin JG, Park JY, Kim MJ, Shon JH, Yoon YR, Cha IJ, Lee SS, Oh SW, Kim SW, Flockhart DA.
Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin.
Drug Metab Dispos. 2002 Oct;30(10):1102-7. - Desta Z, Zhao X, Shin JG, Flockhart DA.
Clinical significance of the cytochrome P450 2C19 genetic polymorphism.
Clin Pharmacokinet. 2002;41(12):913-58. - Jan MW, ZumBrunnen TL, Kazmi YR, VanDenBerg CM, Desai HD, Weidler DJ, Flockhart DA.
Pharmacokinetics of fluvoxamine in relation to CYP2C19 phenotype and genotype.
Drug Metabol Drug Interact. 2002;19(1):1-11. - Tanus-Santos JE, Desai M, Deak LR, Pezzullo JC, Abernethy DR, Flockhart DA, Freedman JE.
Effects of endothelial nitric oxide synthase gene polymorphisms on platelet function, nitric oxide release, and interactions with estradiol.
Pharmacogenetics. 2002 Jul;12(5):407-13. - Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, Wrighton SA.
Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.
Drug Metab Dispos. 2002 Aug;30(8):883-91. - Flockhart DA, Usdin Yasuda S, Pezzullo JC, Knollmann BC.
Teaching rational prescribing: a new clinical pharmacology curriculum for medical schools.
Naunyn Schmiedebergs Arch Pharmacol. 2002 Jul;366(1):33-43. - Gu Z, Lee RY, Skaar TC, Bouker KB, Welch JN, Lu J, Liu A, Zhu Y, Davis N, Leonessa F, Brünner N, Wang Y, Clarke R.
Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-kappaB, and cyclic AMP response element binding with acquired resistance to Faslodex (ICI 182,780).
Cancer Res. 2002 Jun 15;62(12):3428-37.
